Search Results - "Nadolsky, Karl Z"

Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population by Nadolsky, Karl Z

“…INTRODUCTION Obesity is a chronic relapsing progressive disease defined by abnormal or excessive adiposity that may impair health and is staged based on the…”
Get full text

Use of the Term “Lean” for Nonalcoholic Fatty Liver Disease in Individuals With Low Body Mass Index by Nadolsky, Karl Z.

Get full text

Letter to the Editor: "Our Response to COVID-19 as Endocrinologists and Diabetologists" by Nadolsky, Karl Z

Get full text

Once-Weekly Semaglutide in Adults with Overweight or Obesity by Nadolsky, Karl Z, Agarwal, Monica

Get full text

RE: CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY by Nadolsky, Karl Z

Get more information

CYSTATIN C, DIABETIC KIDNEY DISEASE, AND IMPLICATIONS FOR DIABETES MANAGEMENT by Nadolsky, Karl Z

Get more information

Covid-19 & Obesity: Beyond Bmi by Nadolsky, Karl Z, Hurley, Daniel L, Garvey, W Timothy

“…The pandemic of novel coronavirus disease 2019 (COVID-19) has triggered an international crisis resulting in excess morbidity and mortality with adverse…”
Get more information

Once-Weekly Semaglutide in Adults with Overweight or Obesity by Javor, Eugen, Lucijanić, Marko, Skelin, Marko, Khoo, Teck K, Lin, Jack, Nadolsky, Karl Z, Agarwal, Monica, Srivastava, Gitanjali, Kumar, Rekha B, Wilding, John P.H, Calanna, Salvatore, Kushner, Robert F, Rosen, Clifford J, Ingelfinger, Julie R

“…To the Editor: The risk of hypoglycemia in patients who are receiving glucagon-like peptide-1 (GLP-1) analogues as monotherapy is considered to be…”
Get full text

Letter to Editor Response to Covid-19 Endocrinology & Diabetology by Nadolsky, Karl Z

Get full text